Caris Life Sciences, Inc.

CAI Nasdaq SEC CIK 2019410
Follow Caris Life Sciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $275.4M +27% vs same quarter last year
Net income $15.3M −37.3% vs same quarter last year
EPS, diluted $0.05 −37.5% vs same quarter last year
Operating cash flow −$22.2M −135.6% vs same quarter last year
Revenue by quarter
$129.9M
$120.9M
$181.4M
$216.8M
$292.9M
$216.2M
$263.7M
$275.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$812M−$68.1M
FY24$412.3M−$281.9M
FY23$306.1M−$341.4M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−150%−100%−50%0%50%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY255.6%−8.4%
FY24−62.4%−68.4%
FY23−104.4%−111.5%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0$100MFY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$66.9M
FY24−$253.6M
FY23−$298.4M
FY22-
Returned to shareholdersDividends paid and shares bought back
$0$50K$100K$150KFY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$113K
FY24$0
FY23$0
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Caris Life Sciences
  • Healthcare median
−150%−100%−50%0%FY22FY23FY24FY25
Show the numbers
YearCaris Life SciencesHealthcare median
FY25−8.4%−30.6%
FY24−68.4%−47%
FY23−111.5%−58%
FY22-−80.4%